Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles12

RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering RNA (siRNA). To maintain a high level of growth, tumor cells scavenge hi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neoplasia (New York, N.Y.) N.Y.), 2011-04, Vol.13 (4), p.309-319
Hauptverfasser: Shahzad, Mian MK, Mangala, Lingegowda S, Han, Hee Dong, Lu, Chunhua, Bottsford-Miller, Justin, Nishimura, Masato, Mora, Edna M, Lee, Jeong-Won, Stone, Rebecca L, Pecot, Chad V, Thanapprapasr, Duangmani, Roh, Ju-Won, Gaur, Puja, Nair, Maya P, Park, Yun-Yong, Sabnis, Nirupama, Deavers, Michael T, Lee, Ju-Seog, Ellis, Lee M, Lopez-Berestein, Gabriel, McConathy, Walter J, Prokai, Laszlo, Lacko, Andras G, Sood, Anil K
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering RNA (siRNA). To maintain a high level of growth, tumor cells scavenge high-density lipoprotein (HDL) particles by overexpressing its receptor: scavenger receptor type B1 (SR-B1). In this study, we exploited this cellular characteristic to achieve efficient siRNA delivery and established a novel formulation of siRNA by incorporating it into reconstituted HDL (rHDL) nanoparticles. Here, we demonstrate that rHDL nanoparticles facilitate highly efficient systemic delivery of siRNA in vivo , mediated by the SR-B1. Moreover, in therapeutic proof-of-concept studies, these nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 and focal adhesion kinase) in orthotopic mouse models of ovarian and colorectal cancer. These data indicate that an rHDL nanoparticle is a novel and highly efficient siRNA carrier, and therefore, this novel technology could serve as the foundation for new cancer therapeutic approaches.
ISSN:1522-8002
1476-5586